Deignan Charles A. 4
4 · Clearside Biomedical, Inc. · Filed Jan 20, 2021
Insider Transaction Report
Form 4
Deignan Charles A.
Chief Financial Officer
Transactions
- Award
Common Stock
2021-01-18+96,360→ 322,187 total - Award
Stock Option (Right to Buy)
2021-01-18+195,640→ 195,640 totalExercise: $4.01Exp: 2031-01-18→ Common Stock (195,640 underlying)
Footnotes (3)
- [F1]These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2022, January 18, 2023, January 18, 2024 and January 18, 2025, subject to the Reporting Person's continuous service as of each such vesting date, and subject to accelerated vesting in specified circumstances.
- [F2]Includes 5,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2020.
- [F3]One-fourth of the shares underlying this option vest on January 18, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.